Could the Drugs Behind Mounjaro and Zepbound Help Curb Cravings, Not Just Appetite?

I’ve been closely following a fascinating new wave of research lately. It mirrors a phenomenon I am beginning to observe in my own clinical practice, and it is a conversation worth having—carefully and responsibly.

A growing body of research suggests that incretin-based medications—the broader class that includes blockbuster weight-loss and diabetes drugs like tirzepatide (Mounjaro, Zepbound) and semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. (Ozempic, Wegovy)—may do far more than just quiet physical hunger. Early studies indicate they could also dampen cravings for alcohol and other substances by acting directly on the brain’s reward system.

The Gut-Brain Connection: Rewiring the Reward System

Scientists believe this effect occurs because receptors for these hormones (like GLP-1 and GIP) are densely located not just in the gut, but in the brain's core reward and self-control centers, including the mesolimbic dopamineA neurotransmitter that fuels motivation, reward, and pleasure. system.

Reviews of the field suggest this craving-reduction effect may extend across multiple substances, including alcohol, nicotine, and cocaine. Early human data is pointing in the same direction, particularly among patients who also have underlying metabolic conditions or obesity.

Striking Preclinical Evidence

The most compelling, albeit early, findings so far come from animal research. In a 2025 preprint study, researchers found that tirzepatide (which uniquely mimics both GLP-1 and GIP hormones) yielded remarkable results:

• Reduced Intake: Voluntary alcohol drinking in both male and female rodents dropped by roughly 40–65%.
• Behavioral Shifts: It successfully curbed binge-style drinking.
• Prevention: It blocked "relapse" drinking after a period of abstinence, without losing effectiveness over repeated dosing.

The proposed mechanism is particularly notable. Rather than simply suppressing the intake of the substance, the drug appears to blunt the dopamineA neurotransmitter that fuels motivation, reward, and pleasure. "reward" surge that alcohol normally triggers. Essentially, it makes the substance feel less rewarding to the brain.

From the Lab to the Clinic: Fountain Health Experience

At Fountain Health, I have cautiously and selectively explored low-dose, carefully titrated therapy using these medications as part of a comprehensive, closely supervised program for some patients with alcohol and substance use disorders. It is vital to note that this is always alongside, never in place of, established addiction care and behavioral therapy.

Because these medications have profound metabolic and nutritional impacts, rigorous safety protocols are built into our treatment plans from day one. This includes:

• Comprehensive Lab Monitoring: Baseline and ongoing bloodwork to monitor metabolic health.
• Body Composition Tracking: Baseline and follow-up DEXA scans to track bone density and ensure healthy body composition.
• Nutritional Support: Close collaboration with a registered dietitian to protect lean muscle mass and prevent malnutrition.

Within that highly controlled framework, what I have observed anecdotally echoes the preclinical research. Some patients report meaningfully fewer cravings. Furthermore, when they do drink, they report being significantly less likely to continue into a binge pattern.

I share these as individual clinical observations, not the results of a controlled clinical trial.

Important Clinical Caveats

I want to be very clear about the limits, because they matter: this is early, largely preclinical science, and these medications are not FDA-approved to treat addiction. Any such use is off-label, must be individualized, and belongs only within a supervised medical setting with appropriate monitoring and informed consentMaking sure patients understand risks, benefits, and alternatives before starting treatment. A legal and ethical requirement.. The human evidence is still limited, effects vary by substance and by person, side effectsUnintended effects from treatment. (including nausea and mood changes) are real, and clinical trials are ongoing.

References

Tirzepatide attenuates dopamineA neurotransmitter that fuels motivation, reward, and pleasure. reward signaling and suppresses alcohol drinking and relapseA return to substance use after a period of improvement.-like behaviors in rodents. bioRxiv (preprint), 2025; doi:10.1101/2025.08.26.672374. https://www.biorxiv.org/content/10.1101/2025.08.26.672374v1 (Note: preprint — not yet peer-reviewed.)

Mechanisms of GLP-1 in Modulating Craving and AddictionA condition where the brain's reward system drives compulsive use of a substance or behavior, despite harm.: Neurobiological and Translational Insights. Medical Sciences (Med Sci), 2025; 13(3):136. MDPI. https://www.mdpi.com/2076-3271/13/3/136

Novel evidence for tirzepatide, a dual GLP-1/GIP receptor agonist, to reduce the motivation for cocaine in rodents. eBioMedicine (The Lancet), 2026. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00139-8/fulltext